Disruptive Innovation – The Impact Perspectives from Senior Pharma Executives

Provided By:


May 25, 2018

Disruptive Innovation in the Life Science Industry

At a panel session hosted by ICON early in 2018, senior executives from leading pharma companies shared their views on ‘Disruptive Innovation’. The session was chaired by Nuala Murphy (President, Clinical Research Services, ICON) and guest panellists Francesca Wuttke (Managing Director, MSD Global Health Innovation Fund), Dr. William H. Carson (President and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc.) and Badhri Srinivasan (Global Head of Development Operations, Novartis) provided insight into the challenges and barriers to innovation, the likely shape of clinical trials in the future and the important success factors to drive innovation in organisations.

Topics discussed

  • The digital explosion and data tsunami
  • Direct to patient strategies introducing new players to the industry
  • Democratising and destigmatising clinical trials to improve patient recruitment
  • Patient privacy and data protection
  • Choosing the right innovation and the right partner
  • Organisational evolution to deliver innovation
  • Resourcing to drive change
  • Innovative therapies – pushing the boundaries of current practices

Post a Comment

You must be logged in to post a Comment.